Search company, investor...

Longhorn Vaccines & Diagnostics

Founded Year


About Longhorn Vaccines & Diagnostics

Longhorn Vaccines & Diagnostics specializes in molecular tools, assay, and vaccine development. It offers products such as PrimeStore Molecular Transport Medium (MTM), PrimeXtract, and more for storing and stabilizing microbial nucleic acid across sample types. The company was founded in 2006 and is based in Bethesda, Maryland.

Headquarters Location

2 Bethesda Metro Center Suite 910

Bethesda, Maryland, 20814,

United States

Missing: Longhorn Vaccines & Diagnostics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Longhorn Vaccines & Diagnostics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Longhorn Vaccines & Diagnostics News

Egregious Abuse of the PTAB Process Leads to Adverse Decision Sanctions in IPR Proceeding

May 27, 2023

To embed, copy and paste the code into your website or blog: <iframe frameborder="1" height="620" scrolling="auto" src="//" style="border: 2px solid #ccc; overflow-x:hidden !important; overflow:hidden;" width="100%"></iframe> In a per curium order issued under seal May 3, 2023 but recently made public, the Patent Trial and Appeal Board awarded sanctions against Patent Owner, Longhorn Vaccines & Diagnostics, cancelling all challenged claims of its five asserted patents for its “egregious abuse of the PTAB process.” Particularly, the Board determined that Patent Owner, through its counsel, failed to meet its duty of candor and fair dealing before the Board by “selectively and improperly” withholding material information material to the patentability of the claims challenged in the IPR proceeding. In its decision, the PTAB ordered sanctions of adverse judgment as to all challenged claims and denied Patent Owner’s motions to amend. The Board determined that Patent Owner “failed to meet its duty of candor and fair dealing in its actions before the Board” by withholding information relating to biological testing conducted by the company in support of its Patent Owner’s Response. The Board found that Patent Owner proffered evidence “that was intentionally misleading” because it “omits results contrary to Patent Owner’s general position.” The Board also determined that that Patent Owner “intentionally intervened with the evidence of … witness(es) in order to “tailor” the test results and omit relevant results,” supplied this incomplete information to its expert as support for their testimony, and withheld these test results as to its proposed substitute claims in its Motion to Amend. The Dispute Petitioner, Spectrum Solutions LLC, sought inter partes review of five patents owned by Longhorn Vaccines & Diagnostics, LLC relating to biological specimen collection. Patent Owner engaged an independent lab to conduct biological testing in support of its Patent Owner’s Response and Motion to Amend the claims. During Petitioner’s deposition of the independent lab, Petitioner disputed attorney-work-product objections raised by Patent Owner’s counsel relating the lab test results. In response, the PTAB issued an Order authorizing additional questioning on the lab testing and ordering Patent Owner to serve any relevant inconsistent information. Patent Owner ultimately served additional documents relating to its testing, but maintained that “the testing conducted on its behalf … is privileged as attorney work product.” Patent Owner also argued that it complied with its duty of candor “because the withheld data was not “inconsistent with any statement in [its] witnesses’ testimony, Exhibit 2019” and was not “inconsistent with anything that the patent owner has said.” Petitioner filed a Motion for Sanctions, which requested: (1) entering judgment against Patent Owner; (2) holding that a particular reference meets particular claim limitations and precluding Patent Owner from contesting otherwise; and (3) providing Petitioner compensatory expenses, including attorney fees. The Board’s Findings According to the Board, “The testing data that Patent Owner initially withheld … is relevant to the patentability of the claims as we construed them in the institution decisions, … [and] is also relevant to the patentability of the claims as Patent Owner seeks to construe them.” The Board stated that “Patent Owner’s representation to the Board that ‘no other testing exists relating to the conclusions or results presented in Ex. 2019’ … appears wholly untrue.” And, according to the Board, “the test results, and related documentation” that Patent Owner provided to its expert “were misleading at best and omitted information that a declarant reasonably would have considered relevant to the conclusion he reached as to the” prior art. The Board also determined that there was no sound basis for asserting the attorney-work-product privilege for the factual information withheld. According to the Board, “the withheld data appears on its face to be the very type of factual information—research, tests, and experiments pertinent to patentability—that cannot be hidden behind the work product doctrine.” The Board noted that where privileged information may exist, the party may still file the material with the Board under seal to allow the party to comply with its duty of candor and good faith to the Office. Take Aways Remember that the duty of candor due the Office is not limited to the time period when you are prosecuting patent applications prior to issuance. Under Rule 42.11, the duty of candor applies to any proceeding before the Board. See, 37 C.F.R. § 42.11. This includes IPR proceedings. Your mere reliance on the material being privileged as attorney work product likely won’t excuse a failure to properly assert the privilege when filing (and serving) your papers or when presenting witnesses for deposition. If you would like to rely on privilege but are concerned that the privileged information may be material to the patentability, you can file this information with the Board under seal as “Filing Party and Board” in the Board’s electronic filing system. Doing so will allow your privileged information to be shielded while attempting to comply with the duty of candor and good faith and while the Board determines what is material and confirms it is privileged. You may also request authorization for en camera review of the information and briefing to assert a privilege claim before you reach the deposition stage, or as soon as you are aware of the potential issue.

Longhorn Vaccines & Diagnostics Frequently Asked Questions (FAQ)

  • When was Longhorn Vaccines & Diagnostics founded?

    Longhorn Vaccines & Diagnostics was founded in 2006.

  • Where is Longhorn Vaccines & Diagnostics's headquarters?

    Longhorn Vaccines & Diagnostics's headquarters is located at 2 Bethesda Metro Center, Bethesda.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.